In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Issue 5 (10th March 2015)

• Record Type: Journal Article
• Authors: Badali, Hamid; Mohammadi, Rasoul; Mashedi, Olga; de Hoog, G. Sybren; Meis, Jacques F.
• Is Part Of: Mycoses. Volume 58:Issue 5(2015)
• Page Start: 303
• Page End: 307
• Publication Date: 2015-03-10
• Subjects: Pathogenic fungi -- Periodicals; Medical mycology -- Periodicals; 616.969
• DOI: 10.1111/myc.12315
• Languages: English
• ISSNs: 0933-7407

Abstract

<abstract abstract-type="main" id="myc12315-abs-0001"> <title>Summary</title> <p>Despite the common, worldwide, occurrence of dermatophytes, little information is available regarding susceptibility profiles against currently available and novel antifungal agents. A collection of sixty‐eight clinical <italic>Trichophyton</italic> species and <italic>Epidermophyton floccosum</italic> were previously identified and verified to the species level by sequencing the internal transcribed spacer (ITS) regions of rDNA. MICs of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, terbinafine and MECs of caspofungin and anidulafungin were performed based on CLSI M38‐A2. The resulting MIC₉₀s of all strains were, in increasing order, as follows: terbinafine (0.063 mg l⁻¹); posaconazole (1 mg l⁻¹); isavuconazole and anidulafungin (2 mg l⁻¹); itraconazole, voriconazole, amphotericin B, and caspofungin (4 mg l⁻¹) and fluconazole (&gt;64 mg l⁻¹). These results confirm that terbinafine is an excellent agent for treatment of dermatophytosis due to <italic>T. rubrum, T. mentagrophytes, T. verrucosum, T. schoenleinii</italic> and <italic>E. floccosum</italic>. In addition, the new azoles POS and ISA are potentially useful antifungals to treat dermatophytosis. However, the clinical effectiveness of these novel antifungals remains to be determined.</p> </abstract>